Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

OBJECTIVE: Tofogliflozin, a highly selective inhibitor of sodium/glucose cotransporter 2 (SGLT2), induces urinary glucose excretion (UGE), improves hyperglycemia and reduces body weight in patients with Type 2 diabetes (T2D). The mechanisms of tofogliflozin on body weight reduction were investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, M, Takeda, M, Kito, A, Fukazawa, M, Yata, T, Yamamoto, M, Nagata, T, Fukuzawa, T, Yamane, M, Honda, K, Suzuki, Y, Kawabe, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189930/
https://www.ncbi.nlm.nih.gov/pubmed/25000147
http://dx.doi.org/10.1038/nutd.2014.20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189930/
https://www.ncbi.nlm.nih.gov/pubmed/25000147
http://dx.doi.org/10.1038/nutd.2014.20

Ejemplares similares